Department of Orthopaedics, University of Illinois at Chicago, 835 S. Wolcott Avenue E-270 MSS MC 844, Chicago, IL, 60612-7342, USA.
Advocate Lutheran General Hospital, Park Ridge, IL, USA.
Osteoporos Int. 2020 Nov;31(11):2263-2267. doi: 10.1007/s00198-020-05499-6. Epub 2020 Jun 20.
This is the first report describing three ipsilateral femoral stress fractures in a patient taking denosumab.
Multiple reports of atypical femur fractures (AFF) in patients receiving denosumab have emerged recently. Denosumab is an anti-resorptive agent approved for treatment of osteoporosis. It is a human monoclonal antibody which blocks osteoclast activation, maturation, and function.
This is a case report of a 74-year-old female patient who sustained three stress fractures of her left femur.
The patient healed her fractures after intramedullary nailing of the femur and was able to return to her activities.
High index of suspicion is needed in any patient with osteoporosis on denosumab complaining of thigh or groin pain. Careful examination and radiographic studies of both femurs are warranted if AFF is discovered.
这是首例报告描述了一位接受地舒单抗治疗的患者出现同侧股骨应力性骨折。
最近出现了多份关于接受地舒单抗治疗的患者出现非典型股骨骨折（AFF）的报告。地舒单抗是一种抗吸收药物，批准用于治疗骨质疏松症。它是一种人源化单克隆抗体，可阻断破骨细胞的激活、成熟和功能。
这是一位 74 岁女性患者的病例报告，她的左股骨发生了三处应力性骨折。
患者接受股骨髓内钉固定后骨折愈合，能够恢复活动。
任何接受地舒单抗治疗的骨质疏松症患者出现大腿或腹股沟疼痛，都需要高度怀疑。如果发现 AFF，则需要仔细检查和对双侧股骨进行影像学研究。
Zotero 插件